Can vaginal dryness persist during systemic hormone replacement therapy because local vaginal estrogen effect is inadequate?

Menopausal vaginal dryness frequently persists despite systemic hormone replacement therapy (HRT), indicating that systemic delivery does not guarantee adequate localized tissue response.

Local estrogen receptor dynamics

• Receptor-mediated homeostasis: Genitourinary tissue integrity relies on local estrogen receptor alpha (ERα/ESR1) activation. This pathway drives epithelial cell proliferation to maintain a robust, stratified squamous barrier and regulates tissue perfusion to support vital vascular blood flow.
• Microbiome and pH stability: Local ERα activation stimulates epithelial glycogen accumulation. This glycogen is metabolized to support Lactobacillus species, which maintain a healthy, acidic vaginal pH (3.5–4.5) and protect against dysbiosis.

Pathophysiological cascade and intervention

• Tissue degradation: Inadequate local receptor activation—a common limitation of systemic HRT—triggers epithelial thinning, compromised perfusion, glycogen depletion, loss of Lactobacillus dominance, and impaired lubrication. These cellular changes clinically manifest as vaginal dryness and Genitourinary Syndrome of Menopause (GSM).
• Targeted therapy: Supplementing systemic treatment with low-dose local vaginal estrogen (such as creams, tablets, or rings) directly targets and activates local vaginal ERα, reversing tissue atrophy and restoring moisture with minimal systemic absorption.

Bottom line

• Key takeaway: Persistent vaginal dryness during systemic HRT directly reflects insufficient local ERα activation. Combining systemic therapy with targeted, low-dose local vaginal estrogen safely and effectively restores urogenital epithelial thickness, blood flow, and microbiome balance.